110 related articles for article (PubMed ID: 20833263)
1. Personalized medicine: potential impact on the biopharmaceutical industry.
Malik NN; Khan Y
Drug Discov Today; 2010 Nov; 15(21-22):881-3. PubMed ID: 20833263
[No Abstract] [Full Text] [Related]
2. India's drug tests.
Padma TV
Nature; 2005 Jul; 436(7050):485. PubMed ID: 16049471
[No Abstract] [Full Text] [Related]
3. Cutting the cost of drug development?
Rawlins MD
Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531
[No Abstract] [Full Text] [Related]
4. Personalized medicine: a paradigm for a sustainable pharmaceutical industry?
Chackalamannil S; Desai MC
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):443-5. PubMed ID: 19562640
[TBL] [Abstract][Full Text] [Related]
5. America's other drug problem: how the drug industry distorts medicine and politics.
Relman AS; Angell M
New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
[No Abstract] [Full Text] [Related]
6. Placing bets on biotech.
Weintraub K
Cancer Discov; 2011 Nov; 1(6):462. PubMed ID: 22586641
[No Abstract] [Full Text] [Related]
7. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
[TBL] [Abstract][Full Text] [Related]
8. Torching the Haystack: modelling fast-fail strategies in drug development.
Lendrem DW; Lendrem BC
Drug Discov Today; 2013 Apr; 18(7-8):331-6. PubMed ID: 23246516
[TBL] [Abstract][Full Text] [Related]
9. Industry sponsorship in research and publishing: who is really to blame for perceived bias?
Amsden GW
Ann Pharmacother; 2004 Apr; 38(4):714-6. PubMed ID: 14982974
[No Abstract] [Full Text] [Related]
10. Independent medical research.
van der Meer JW; de Gier AM; van Swaaij WP; Katan MB
Neth J Med; 2007 Apr; 65(4):124-6. PubMed ID: 17452759
[No Abstract] [Full Text] [Related]
11. Overcoming the obstacles in the pharma/biotech industry: 2009 update.
Graul AI; Revel L; Tell M; Rosa E; Cruces E
Drug News Perspect; 2010; 23(1):48-63. PubMed ID: 20155219
[TBL] [Abstract][Full Text] [Related]
12. Implications of pharmaceutical industry funding on clinical research.
Lexchin JR
Ann Pharmacother; 2005 Jan; 39(1):194-7. PubMed ID: 15562137
[TBL] [Abstract][Full Text] [Related]
13. The pharmaceutical industry--prices and progress.
Scherer FM
N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432
[No Abstract] [Full Text] [Related]
14. R&D policy, agency costs and innovation in personalized medicine.
Yin W
J Health Econ; 2009 Sep; 28(5):950-62. PubMed ID: 19671480
[TBL] [Abstract][Full Text] [Related]
15. Market watch: industry perspectives on personalized medicine.
Zuckerman R; Milne CP
Nat Rev Drug Discov; 2012 Mar; 11(3):178. PubMed ID: 22378258
[No Abstract] [Full Text] [Related]
16. Strategic groups in the biopharmaceutical industry: implications for performance.
Erden Z; von Krogh G; Nytorp C; Hultberg M
Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
[TBL] [Abstract][Full Text] [Related]
17. The brains behind blockbusters.
Couzin J
Science; 2005 Jul; 309(5735):728. PubMed ID: 16051786
[No Abstract] [Full Text] [Related]
18. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
Scattereggia J
IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
[TBL] [Abstract][Full Text] [Related]
19. Attrition and translation.
Duyk G
Science; 2003 Oct; 302(5645):603-5. PubMed ID: 14576424
[TBL] [Abstract][Full Text] [Related]
20. Medicine and the pharmaceutical industry.
Baxter P
Dev Med Child Neurol; 2006 Aug; 48(8):627. PubMed ID: 16836771
[No Abstract] [Full Text] [Related]
[Next] [New Search]
